Sublingual immunotherapy in southern Africa: lessons learned

Area of Science:

• Allergy and Immunology
• Clinical Research

Background:

• Sublingual immunotherapy (SLIT) is a recommended treatment for allergic rhinitis and associated asthma in South Africa, targeting house dust mites and grass pollens.
• Local studies confirm the efficacy and safety of European SLIT vaccines but reveal variability in patient responses.

Purpose of the Study:

• To assess the factors influencing patient adherence and completion of the 3-year SLIT treatment course.
• To investigate the reasons for patient discontinuation of SLIT.
• To identify potential immunologic markers associated with SLIT treatment response.

Main Methods:

• Analysis of clinical data from patients undergoing SLIT for allergic rhinitis.
• Utilisation of standardized rhinitis quality-of-life questionnaires for patient follow-up.
• Ongoing research to identify immunologic markers of SLIT responders.

Main Results:

• Regular patient follow-up and standardized questionnaires enhance compliance and completion rates for the 3-year SLIT program.
• Most treatment discontinuations occur within the first year, primarily due to logistical and financial barriers, not adverse effects.
• Heterogeneity in clinical responses to European SLIT vaccines has been observed.

Conclusions:

• SLIT is a viable treatment for allergic rhinitis in South Africa, but patient support is crucial for adherence.
• Addressing practical challenges is key to improving long-term SLIT treatment success.
• Further research into immunologic markers may help personalize SLIT therapy and predict treatment outcomes.